Galapagos Aktie

28,70 EUR +0,60 EUR +2,14 %

15:44:06

BER

27,78 EUR +1,38 EUR +5,23 %

22.07.2025

GVIE

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.1,84 Mrd. EUR

KGV23,59Div. Rendite0,00%

WKNA0EAT9

ISINBE0003818359

SymbolGLPGF

Galapagos Aktien News

Sortieren:Datum Meistgelesen

19.12.23GlobeNewswireGalapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301

09.12.23GlobeNewswireGalapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101

07.12.23GlobeNewswireGalapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023

06.11.23PR NewswireLandmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care

02.11.23GlobeNewswireGalapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023

30.10.23GlobeNewswireGalapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma

19.09.23GlobeNewswireGalapagos appoints Simon Sturge to its Board of Directors

28.08.23GlobeNewswireGalapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus

03.08.23GlobeNewswireGalapagos announces first half-year 2023 financial results

15.06.23GlobeNewswireGalapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

12.06.23GlobeNewswireGalapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board

05.06.23GlobeNewswireGalapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress

23.05.23GlobeNewswireGalapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis

22.05.23GlobeNewswireGalapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023

05.05.23GlobeNewswireGalapagos creates new subscription right plans

04.05.23GlobeNewswireGalapagos announces first quarter 2023 financial results

02.05.23GlobeNewswireGalapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer

26.04.23GlobeNewswireGalapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis

25.04.23GlobeNewswireGalapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting

30.03.23GlobeNewswireGalapagos and NovAliX enter into an integrated drug discovery collaboration

23.03.23GlobeNewswireGalapagos publishes 2022 annual report and announces Annual Shareholders’ Meeting

20.03.23GlobeNewswireGalapagos increases share capital through subscription right exercises

27.02.23GlobeNewswireGalapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023

23.02.23GlobeNewswireGalapagos announces full year 2022 results and outlook for 2023

09.02.23GlobeNewswireGalapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL

08.02.23GlobeNewswireGalapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease

11.11.22GlobeNewswireGalapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

08.11.22GlobeNewswireGalapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

04.11.22GlobeNewswireGalapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

03.11.22GlobeNewswireGalapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results

17.10.22GlobeNewswireGalapagos to host its R&D Update 2022 in New York on 4 November 2022

06.10.22GlobeNewswireGalapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress

03.10.22GlobeNewswireGalapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies

27.09.22GlobeNewswireGalapagos increases share capital through subscription right exercises

29.08.22GlobeNewswireGalapagos receives transparency notification from FMR LLC

24.08.22GlobeNewswireGalapagos to present at upcoming investor conferences

18.08.22GlobeNewswireGalapagos receives transparency notification from FMR LLC

08.08.22GlobeNewswireGalapagos receives transparency notification from FMR LLC

04.08.22GlobeNewswireFirst key steps in pipeline rebuild and strong commercial progress in H1 2022

Galapagos News

Galapagos News: auf dieser Seite finden Sie alle Galapagos News und Nachrichten zur Galapagos Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Galapagos News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Galapagos News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.